Pipeline of Targeted Nanosphere (TNS) products

NanoValent Pipeline



The following publications describe the technologies and projects referenced above:

1. Salvador-Morales, C, Zhang, L, Langer, R, Farokhzad, OC (2009) Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30: 2231–2240.

2. Llombart-Bosch A, Navarro S. (2001) Immunohistochemical detection of EWS and FLI-1 proteins in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol. 9(3): 255-60.

3. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol. 52(7): 1103-11.

4. Xu G, Zhang W, Ma MK, McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res. (8): 2605-11.

5. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Critical Reviews in Therapeutic Drug Carrier Systems, 26: 523–580.

6. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res. 65: 8984-92.

7. Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K. (2015) CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. Clin Cancer Res. 21(1): 146-56.

8. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, LiuB, Marks JD, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxicpolymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012;2012:126906. PubMed PMID: 23024593; PubMed Central PMCID:PMC3447386.

9. Kang, H, Shahbazian V, Schafenacker A, Nagy J, Triche T: Development of selective therapy of childhood ALL and Ewing’s sarcoma using targeted0hybrid polymerized liposomal nanoparticles (HPLN). In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014; Cancer Res 2014; 74 (19 Suppl): Abstract nr 5424.

10. Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, CruzRE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenograftsis associated with high exposure of tumor to drug and high SLFN11 expression.Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.PubMed PMID: 25733708.

11. Kang, H, Nagy, J Triche, T: Targeted therapy of leukemia and Ewing’s sarcoma by human antibody-targeted nanoparticles. AACR Mini-Symposium :New Molecular Advances in Pediatric Cancer”, AACR Annual Meeting, 2016.

12. Park, Y., A. C. Luce, R. D. Whitaker, B. Amin, M. Cabodi, R. J. Nap, I. Szleifer, R. O. Cleveland, J. O. Nagy and J. Y. Wong (2012). “Tunable diacetylene polymerized shell microbubbles as ultrasound contrast agents.” Langmuir 2012 28(8): 3766-72 PubMed PMID:22260537

13. Park, Y., T.A. Pham, C. Beigie, M. Cabodi, R.O. Cleveland, J.O Nagy, J. Y. Wong, “Monodisperse Micro-Oil Droplets Stabilized by Polymerizable Phospholipid Coatings as Potential Drug Carriers”, Langmuir 2015, 31, 9762 PubMed PMID: 26303989.

14. Park YC, Zhang C, Kim S, Mohamedi G, Beigie C, Nagy JO, Holt RG, Cleveland RO, Jeon NL, Wong JY. “Microvessels-on-a-Chip to Assess Targeted Ultrasound-Assisted Drug Delivery” ACS applied materials & interfaces. 2016; 8(46):31541-31549 PubMed PMID: 27781429

15. Girgis MD, Federman N, Rochefort MM, McCabe KE, Wu AM, Nagy JO, Denny C, Tomlinson JS “An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles” The Journal of surgical research. 2013; 185(1):45-55. PubMed 23827791